Incyte Corp. buy stratec
Start price
19.02.20
/
50%
€75.44
Target price
04.11.21
€100.00
Performance (%)
-22.53%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. The prediction for Incyte Corp. disappointed with a performance of -22.53%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | -0.305% | -0.305% | 30.131% | 22.718% |
| iShares Core DAX® | 0.191% | 4.892% | 22.046% | 64.626% |
| iShares Nasdaq 100 | -0.614% | 2.901% | 7.804% | 109.421% |
| iShares Nikkei 225® | 0.599% | 7.404% | 22.218% | 57.591% |
| iShares S&P 500 | -0.036% | 3.489% | 4.833% | 68.003% |
Comments by stratec for this prediction
In the thread Incyte Corp. diskutieren
Incyte (NASDAQ:INCY) perks up 2% premarket on light volume on the heels of its announcement of positive results from a second Phase 3 clinical trial, TRuE-AD1, evaluating ruxolitinib cream 0.75% or 1.5% in patients at least 12 years old with mild-to-moderate atopic dermatitis (AD). The study met the primary endpoint of a statistically significant proportion of treated patients achieving clear or almost clear skin at week 8 compared to vehicle (placebo). A sister Phase 3, TRuE-AD2, was also successful. Marketing applications should be the next step.
Kursziel geändert auf 100,0
In the thread Trading Incyte Corp.
Die von stratec gewählte maximale Laufzeit wurde überschritten